Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetrorelix Pamoate in Symptomatic Benign Prostatic Hypertrophy (Z-036)
NCT00663858Phase 3Completed
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- Mar 2008
- Primary completion
- Sep 2009
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Cetrorelix 78+78, Cetrorelix 78 + Placebo and Placebo (3 arms). Primary endpoint: International Prostate Symptom Score at 52 weeks. Started Mar 2008; status: completed.
02
Drugs
cetrorelix
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00663858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00663858.